Jump to content

Jean-Christophe Leroux

Add links
From Wikipedia, the free encyclopedia
Jean-Christophe Leroux (2020) https://galenik.ethz.ch/

Dr. Jean-Christophe Leroux (born April 27, 1969) is a French-Canadian full professor of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the Swiss Federal Institute of Technology ETH Zürich.[1] His research is mainly focused on broadening the field of drug delivery, and the development of biodetoxification systems for the treatment of metabolite disorders. Additionally, he has made important contributions to the field of biomaterials for use in drug delivery.

Education

[edit]

Leroux trained as a pharmacist at the University of Montreal (Canada), and received his Ph.D. in Pharmaceutical Sciences (1995) from the University of Geneva (Switzerland). From 1996 to 1997, he was a postdoctoral fellow at University of California, San Francisco.

Career

[edit]

Leroux was appointed professor at the University of Montreal in 1997 where he worked until he joined the ETH Zürich. From 2001 to 2010, he held the Tier 2 Canada research chair in drug delivery. He was the chair of the institute of Pharmaceutical Sciences at the ETH Zürich from 2014 to 2016, and from 2021 to 2023.

Leroux has made fundamental and applied contributions to the fields of colloids, biomaterials, and drug delivery.[2][3][4][5][6][7][8] He has published over 270 peer-reviewed manuscripts in top-ranked scientific journals, 14 book chapters and is co-inventor on several patents. Jean-Christophe Leroux is one of the most cited scientists in pharmacy and pharmacology.[9][10]

Leroux was the associate editor of the European Journal and Pharmaceutics and Biopharmaceutics from 2006 to 2012, and of the Journal of Controlled Release from 2012 to 2017.

In 2015, Leroux co-founded the ETH spin-off companies Versantis AG[11] and Inositec AG[12] that are developing drugs for the treatment of hyperammonemia and vascular calcification, respectively. Inositec AG was acquired by Vifor Pharma in Nov-2021 for the development of treatments against calcification disorders at all stages of chronic kidney disease.[13] Versantis AG was acquired by Genfit in Sep-2022 including their team of experts to complements their research on highly unmet needs such as ACLF (acute-on-chronic liver failure).[14]

Awards and recognition

[edit]

2023

[edit]
  • Bioconjugate Chemistry Lectureship Award[15]

2022

[edit]
  • Maurice-Marie Janot Award - Association de Pharmacie Galénique Industrielle[16][17]
  • Samyang Award in honor of Sung Wan Kim- Controlled Release Society[18]
  • Fellow, National Academy of Pharmacy (France)[19]

2021

[edit]
  • Highly Cited Researcher in Pharmacology and Toxicology-Web of Science
  • Dandelion Entrepreneurship Award - ETH Zurich[20]
  • Grand Prix de l`Académie nationale de Pharmacie[21]
  • Centennial Innovation Award in Research and Development – University of Montreal[22]

2020

[edit]
  • Elected to membership in the European Academy of Sciences[23]
  • ERC Advanced Grant[24]

2019

[edit]
  • Fellow of the American Association of Pharmaceutical Scientists[25]

2018

[edit]

2017

[edit]
  • Highly Cited Researcher 2017 - Clarivate Analytics

2016

[edit]
  • Highly Cited Researcher 2016 - Thomson Reuters
  • American Association of Pharmaceutical Scientists Lipid Based Drug Delivery Outstanding Research award

2015

[edit]
  • Phoenix Prize, Pharmaceutical Technology
  • Highly Cited Researcher 2015 - Thomson Reuters

2014

[edit]
  • Fellow of the Controlled Release Society
  • APV[clarification needed] Research Award for Outstanding Achievements in Pharmaceutical Sciences
  • Highly Cited Researcher 2014 - Thomson Reuters

2010

[edit]

2008

[edit]
  • Steacie Fellowship

2004

[edit]
  • Controlled Release Society Young Investigator Award

2003

[edit]

2002

[edit]
  • Pfizer – Actualités Pharmaceutiques award (Research)

References

[edit]
  1. ^ "Galenik".
  2. ^ Kang N, Perron ME, Prud'homme RE, Zhang Y, Gaucher G, Leroux JC (2005). "Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability". Nano Lett. 5 (2): 315–319. Bibcode:2005NanoL...5..315K. doi:10.1021/nl048037v. PMID 15794618.
  3. ^ Leroux JC (2007). "Injectable nanocarriers for biodetoxification". Nat Nanotechnol. 2 (11): 679–684. Bibcode:2007NatNa...2..679L. doi:10.1038/nnano.2007.339. PMID 18654405.
  4. ^ Pinier M, Verdu E, Nasser-Eddine M, David CS, Vézina A, Rivard N, Leroux JC (2009). "Suppression of gliadin-induced toxicity on the intestinal epithelium by polymeric binders". Gastroenterology. 136 (1): 288–298. doi:10.1053/j.gastro.2008.09.016. PMID 18992747.
  5. ^ Fuhrmann G, Grotzky A, Lukic R, Matoori S, Luciani P, Yu H, Zhang B, Walde P, Schlüter D, Gauthier MA, Leroux JC (2013). "Sustained gastrointestinal activity of dendronized polymer–enzyme conjugates". Nat Chem. 5 (7): 582–589. Bibcode:2013NatCh...5..582F. doi:10.1038/nchem.1675. PMID 23787748.
  6. ^ Forster V, Signorell RD, Roveri M, Leroux JC (2014). "Liposome-supported peritoneal dialysis for detoxification of exogenous drugs and endogenous metabolites". Sci Transl Med. 6 (258): 258ra141. doi:10.1126/scitranslmed.3009135. PMID 25320233. S2CID 1961807.
  7. ^ Forster V, Leroux JC (2015). "Nano-antidotes for drug overdose and poisoning". Sci Transl Med. 7 (290): 290ps14. doi:10.1126/scitranslmed.3008736. PMID 26041703. S2CID 41138147.
  8. ^ Liang K, Carmone S, Brambilla D, Leroux JC (2018). "3D printing of a wearable personalized oral delivery device: a first-in-human study". Sci Adv. 4 (5): 4:eaat2544. Bibcode:2018SciA....4.2544L. doi:10.1126/sciadv.aat2544. PMC 5942915. PMID 29750201. S2CID 13718839.
  9. ^ "Clarivate". Archived from the original on 2019-02-20. Retrieved 2019-03-15.
  10. ^ "Jean-Christophe Leroux's Publons profile". publons.com. Retrieved 2022-04-05.
  11. ^ "Versantis".
  12. ^ "Inositec".
  13. ^ "Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG". Vifor Pharma. Retrieved 2022-04-05.
  14. ^ "Versantis to be acquired by GENFIT, combining forces to continue the development of its revolutionary therapeutics for patients with liver diseases". www.venturekick.ch. Retrieved 2024-02-05.
  15. ^ axial.acs.org https://axial.acs.org/biology-and-biological-chemistry/dr-jean-christophe-leroux-wins-the-2023-bioconjugate-chemistry-lectureship-award. Retrieved 2024-02-05. {{cite web}}: Missing or empty |title= (help)
  16. ^ "List of recipients of the Maurice-Marie Janot Award - APGI - Association de Pharmacie Galénique Industrielle". www.apgi.org/. Retrieved 2022-04-05.
  17. ^ "Maurice-Marie Janot Award for prof. Jean-Christophe Leroux". galenik.ethz.ch. 5 April 2022. Retrieved 2022-04-05.
  18. ^ "Prof. Leroux receives a Samyang CRS Award in honor of Sung Wan Kim". galenik.ethz.ch. 5 April 2022. Retrieved 2022-04-05.
  19. ^ "Académie Nationale de Pharmacie - Les membres". www.acadpharm.org. Retrieved 2024-02-05.
  20. ^ "Dandelion Entrepreneurship Award for Prof. Leroux!". galenik.ethz.ch. 18 October 2021. Retrieved 2022-04-05.
  21. ^ "The Grand Prix de l'Académie Nationale de Pharmacie for Jean-Christophe Leroux". galenik.ethz.ch. 28 June 2021. Retrieved 2022-04-05.
  22. ^ "Professor Leroux has received the Centennial Innovation Award in R&D". galenik.ethz.ch. 12 April 2021. Retrieved 2022-04-05.
  23. ^ "Jean-Christophe Leroux elected member of the European Academy of Sciences". galenik.ethz.ch. 22 June 2020. Retrieved 2022-04-05.
  24. ^ "ERC Advanced Grants for two ETH researchers". ethz.ch. 31 March 2020. Retrieved 2020-05-22.
  25. ^ "Fellows - American Association of Pharmaceutical Scientists". www.aaps.org. Retrieved 2020-05-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jean-Christophe_Leroux&oldid=1237672465"